Resources

Selected
  • Systematic reviews (SYSVAC)
Type of publications
Regions
Diseases
Vaccine topics
Target population
Publication date

3220 results found

2023 ∙ Cheng, M. Q. Li, R. Luo, X. Chen, J. Y. Bai, Z. P. Zhao, P. Weng, Z. Y. Song, G.

Immunogenicity and safety of adjuvant-associated COVID-19 vaccines: A systematic review and meta-analysis of randomized controlled trials

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Zhao, T. Yang, Z. Wu, Y. Yang, J.

Immunogenicity and safety of COVID-19 vaccines among people living with HIV: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Carregaro, R. L. Roscani, A. N. C. P. Raimundo, A. C. S. Ferreira, L. Vanni, T. da Graça Salomão, M. Probst, L. F. Viscondi, J. Y. K.

Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews

  • All age groups
  • Influenza
  • Safety
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
High
2023 ∙ Nave, L. Margalit, I. Tau, N. Cohen, I. Yelin, D. Lienert, F. Yahav, D.

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • All age groups
  • Smallpox
  • Mpox
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Wei, X. Tan, X. Guan, Q. Zhang, R. Lei, S. Wei, S.

Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis

  • Newborn
  • Children
  • Influenza
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Low
2023 ∙ Marantos, T. Kyriazopoulou, E. Lekakis, V. Voumvourakis, K. I. Tsiodras, S.

Immunogenicity and safety of vaccines in multiple sclerosis: A systematic review and meta-analysis

  • Adults
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Feng, S. McLellan, J. Pidduck, N. Roberts, N. Higgins, J. P. T. Choi, Y. Izu, A. Jit, M. Madhi, S. A. Mulholland, K. Pollard, A. J. Temple, B. Voysey, M.

Immunogenicity and seroefficacy of 10-valent and 13-valent pneumococcal conjugate vaccines: a systematic review and network meta-analysis of individual participant data

  • Newborn
  • Children
  • Pneumococcal disease
  • Efficacy/effectiveness
  • Administration
Methodological quality (AMSTAR 2):
Low
2023 ∙ Vasconcelos, Z. S. Salem, H. A. Veiga, S. P. Lima, F. E. B. Gonçalves, Crds Santos, E. C. D. Brandão, A. R. J. Couceiro, K. N. Guerra, J. A. O. Guerra, Mdgvb

Immunogenicity Characterization of COVID-19 Vaccines: A Systematic Review and Meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Al-Haideri, M. Mohammad, T. A. M. Darvishzadehdeldari, S. Karbasi, Z. Alimohammadi, M. Faramarzi, F. Khorasani, S. Rasouli, A. Tahmasebi, S. Darvishi, M. Akhavan-Sigari, R.

Immunogenicity of COVID-19 vaccines in adult patients with autoimmune inflammatory rheumatic diseases: A systematic review and meta-analysis

  • Adults
  • Older adults
  • COVID-19
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2023 ∙ Griffin, D. W. Pai Mangalore, R. Hoy, J. F. McMahon, J. H.

Immunogenicity, effectiveness and safety of SARS-CoV-2 vaccination in people living with HIV: A systematic review and meta-analysis

  • All age groups
  • COVID-19
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
Loading...